Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Processa Pharmaceuticals received an amended Schedule 13G showing that investors Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported beneficial ownership of 200,000 shares of common stock issuable upon exercise of a warrant held by Intracoastal.
As of December 31, 2025, these warrant shares represented approximately 8.1% of Processa’s common stock, based on 2,265,768 shares outstanding as of December 12, 2025 plus the 200,000 warrant shares. The filers report shared voting and dispositive power over all 200,000 shares and certify the holding is not for the purpose of changing or influencing control.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Processa Pharmaceuticals (PCSA) is reported in this Schedule 13G/A?
The filing reports beneficial ownership of 200,000 shares of common stock. These shares are issuable upon exercise of a warrant held by Intracoastal Capital LLC and represent approximately 8.1% of Processa’s common stock based on the outstanding share count cited.
Who are the reporting persons in the Processa (PCSA) Schedule 13G/A filing?
The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. Kopin and Asher are U.S. individuals, while Intracoastal is a Delaware limited liability company, and together they are treated as a group of reporting holders.
How was the 8.1% ownership in Processa (PCSA) calculated in the filing?
The 8.1% figure is based on 2,265,768 Processa shares outstanding plus 200,000 warrant shares. The calculation uses the issuer’s reported outstanding shares as of December 12, 2025 and adds the common stock issuable upon exercise of the Intracoastal warrant.
Is the Intracoastal Capital LLC position in Processa (PCSA) a passive investment?
The filers certify the securities are not held to change or influence control. They state the shares were not acquired and are not held for control-related purposes, consistent with a passive investment stance under the Schedule 13G framework.
What voting and dispositive power do the reporting persons have over Processa (PCSA) shares?
The filing reports shared voting and dispositive power over 200,000 shares. Each reporting person lists zero sole voting or dispositive power and shared power over the full 200,000 warrant shares of Processa common stock.
What triggered this amended Schedule 13G for Processa Pharmaceuticals (PCSA)?
The statement reflects ownership as of December 31, 2025. At that date, the reporting persons may be deemed to beneficially own 200,000 Processa shares via a warrant, crossing the 5% threshold that requires Schedule 13G reporting and subsequent amendments.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Processa Pharmaceuticals, Inc.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
74275C403
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
74275C403
1
Names of Reporting Persons
Mitchell P. Kopin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
200,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
200,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
200,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
74275C403
1
Names of Reporting Persons
Daniel B. Asher
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
200,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
200,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
200,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
74275C403
1
Names of Reporting Persons
Intracoastal Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
200,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
200,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
200,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Processa Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
601 21st Street, Suite 300 Vero Beach, FL 32960
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)
Address or principal business office or, if none, residence:
The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)
Citizenship:
Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)
Title of class of securities:
Common stock, par value $0.0001 per share
(e)
CUSIP No.:
74275C403
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on December 31, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 200,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the "Intracoastal Warrant"), and all such shares of Common Stock represent beneficial ownership of approximately 8.1% of the Common Stock, based on (1) 2,265,768 shares of Common Stock outstanding as of December 12, 2025, as reported by the Issuer, plus (2) 200,000 shares of Common Stock issuable upon exercise of the Intracoastal Warrant.
(b)
Percent of class:
8.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
200,000
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
200,000
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
